A new study has linked moderate-to-severe obstructive sleep apnea (OSA), characterized by low oxygen levels overnight, with an increased risk of developing wet age-related macular degeneration (AMD).
Prevent Blindness announces its fourth annual Geographic Atrophy Awareness Week, December 2 to 8, 2024. The organization ...
Prevent Blindness, the nation's leading nonprofit eye health organization, is announcing Dec. 2-8, 2024, as its fourth annual Geographic Atrophy (GA) Awareness Week. GA is an advanced form of dry ...
Findings from a post hoc analysis of the AREDS and AREDS2 studies were presented at the recent American Academy of ...
HAYWARD, CA, USA I1, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first ...
The US FDA has issued a CRL for sNDA of Astellas Pharma’s IZERVAY, a treatment for geographic atrophy (GA) secondary to AMD.
Ocugen (OCGN) announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa ...
Investing.com - Shares of biopharmaceutical firm Apellis Pharmaceuticals Inc (NASDAQ: APLS) surged 16.44% to $31 on Tuesday after the FDA delayed the approval of a drug from rival Astellas Pharma.
Ocugen (NASDAQ:OCGN) reported positive Phase 1 data for its gene therapy candidate OCU410 in the treatment of geographic ...
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...